Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
VKTX Stock Chart & Stats
$35.40
$0.22(0.67%)
At close: 4:00 PM EST
$35.40
$0.22(0.67%)
Day’s Range― - ―
52-Week Range$18.92 - $43.55
Previous CloseN/A
Volume7.75M
Average Volume (3M)2.97M
Market Cap
$3.98B
Enterprise Value$2.85B
Total Cash (Recent Filing)$714.57M
Total Debt (Recent Filing)$755.00K
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Feb 11, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding113,036,350
10 Day Avg. Volume2,446,947
30 Day Avg. Volume2,968,403
Financial Highlights & Ratios
PEG Ratio-3.63
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-49.98
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.39
Forecast
1Y Price Target
$97.27Price Target Upside174.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessEli Lilly's Phase 3 ATTAIN-MAINTAIN trial provides external validation for Viking's oral VK2735 program, supporting its long-term weight maintenance strategy.
Market EnthusiasmThe rapid pace of enrollment is a reflection of enthusiasm for VK2735.
Strategic AdvantagesViking's plan to transition patients from subcutaneous to oral formulations of the same molecule, VK2735, is seen as a key differentiator that supports a seamless and predictable transition.
Bears Say
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $18.92 and its highest was $43.55 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.98B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Feb 11, 2026 which is in 50 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Oct 22, 2025. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.71 by -$0.1.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 113,036,350 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.71. Following the earnings report the stock price went up 7.957%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.27 (174.77% Upside)
$97.27 (174.77% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 312.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.18%
12-Months-Change
Fundamentals
Return on Equity
-29.23%
Trailing 12-Months
Asset Growth
-21.16%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company is engaged in research and development activities aimed at advancing its portfolio of drug candidates, which target conditions such as liver disease, muscle wasting, and other metabolic disorders. Viking Therapeutics' strategy involves leveraging its expertise in drug discovery and development to address unmet medical needs with its innovative small molecule therapeutics.
VKTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials for obesity treatments, with positive Phase II results and the initiation of Phase III trials. However, the financial report showed increased losses and decreased cash reserves.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$97.27
▲(174.77% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
2.83% Insiders
18.63% Mutual Funds
9.18% Other Institutional Investors
56.26% Public Companies and Individual Investors